CNS Pharmaceuticals Inc. CNSP Archives - Page 13 of 22

ThursdayMar 31, 2022 9:00 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Reiterates Commitment to Operational Excellence, Advancing Berubicin Recognition

In a video message to shareholders, CEO John Climaco detailed the operational and clinical progress made by lead drug candidate Berubicin despite market volatility and share price fluctuations CNS is currently enrolling patients into a potentially pivotal global drug trial of Berubicin for recurrent glioblastoma multiforme Interim analysis of the trial is currently expected as early as the first quarter of 2023, once 30-50% of trial patients have been on the study for six months CNS Pharmaceuticals (NASDAQ: CNSP), a clinical-stage biotech company specializing in developing novel treatments for primary and metastatic cancers of the brain and central nervous system,…

TuesdayMar 29, 2022 9:00 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Provides Update on Advances in Brain Cancer Drugs and Operational Financials

Texas-based CNS Pharmaceuticals is a novel brain cancer drug developer that is building a series of global clinical trials for its lead drug candidate, Berubicin CNS began dosing patients in a global trial last September to evaluate Berubicin in treating glioblastoma multiforme (“GBM”), currently an incurable brain cancer CNS received FDA Fast Track designation for Berubicin in June 2021 and FDA Orphan Drug designation for Berubicin in June 2020 Berubicin is a novel anthracycline capable of crossing the blood-brain barrier The company received approval from Switzerland’s swissethics organization for Berubicin trials there, boosting CNS’s efforts at a global response to…

WednesdayMar 23, 2022 1:48 pm

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Participate at the 2022 Virtual Growth Conference

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system (“CNS”), today announced that its CEO John Climaco will participate at the 2022 Virtual Growth Conference. The event, presented by Maxim Group LLC and hosted by M-Vest, is slated to take place March 28-30, 2022. In addition to the company's corporate presentation available on demand for registered attendees, Climaco will participate in a live fireside chat moderated by Jason McCarthy, PhD, Head of Biotechnology Research at Maxim Group, at 2:30 p.m. ET on Wednesday,…

ThursdayMar 17, 2022 2:44 pm

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Discusses Significant Milestone in Advancing Berubicin

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, recently participated in the Virtual Investor 2022 Top Picks Conference. The company’s CEO John Climaco provided a corporate presentation and participated in a moderated questions and answer session during the event. Berubicin, a novel anthracycline and the first in its drug class to appear to cross the blood-brain barrier, is CNS Pharmaceuticals’ lead drug candidate. “The company is currently developing treatments using Berubicin for serious brain and central nervous system oncology indications, including glioblastoma…

WednesdayMar 09, 2022 12:39 pm

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reiterates Progress for Lead Product Candidate, Addresses Recent Share Price Activity in Video to Shareholders

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system (“CNS”), today released a video to shareholders that reiterates its operational and clinical progress for lead product candidate, Berubicin, and addresses recent share price activity. “The divergence that exists between our operational strength and share price is top of mind for myself and the whole team at CNS Pharmaceuticals. As a shareholder of CNS Pharma, I share in the frustrations as it pertains to the share price and fluctuation in the market – both…

MondayMar 07, 2022 11:15 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Gives Corporate Presentation, Q&A Session at Virtual Investor 2022 Top Picks Conference

The company also participated in the H.C. Wainwright BioConnect Conference earlier in January CNS Pharmaceuticals recently received approval from swissethics for a pivotal Berubicin and GBM clinical trial The five-year survival rate for GBM is only 6.8%, with the average patient population surviving 12 to 18 months after diagnosis CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, recently participated in the Virtual Investor 2022 Top Picks Conference. During the event, CEO John Climaco provided a corporate presentation and then participated in a…

ThursdayMar 03, 2022 12:36 pm

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces 2021 Financial Results, Corporate Update

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system (“CNS”), today reported its financial results for the year ended Dec. 31, 2021. The company also provided a clinical update of its anti-cancer drug candidates currently in development for the treatment of primary and metastatic brain and CNS cancer. “Operationally 2021 was a terrific year for the company as we established the global framework for building and expanding our potentially pivotal clinical study of Berubicin for the treatment of GBM. Our priority remains focused…

WednesdayFeb 02, 2022 2:44 pm

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Laying Robust Foundation for Potentially Pivotal Global Trial

CNS Pharmaceuticals (NASDAQ: CNSP) recently received approval from swissethics, the umbrella organization of the cantonal Ethics Committees in Switzerland. The first from a European Ethics Committee, the approval marks a significant milestone for the company as it journeys toward its potentially pivotal study of Berubicin, an anthracycline, for the treatment of Glioblastoma Multiforme (“GBM”). The approval also partly fulfills CNS’s goal of seeing Berubicin approved for the potential treatment of GBM globally. GBM is one of the most aggressive, deadly and treatment-resistant cancers that form in the brain. “So far, the company has selected tens of clinical sites across the…

TuesdayJan 25, 2022 11:14 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Marks Significant Milestone in Pursuit of Berubicin Approval for Global GBM Treatment, Raises $11.5 Million from Private Placement

CNS Pharmaceuticals received approval from swissethics for its potentially pivotal study of Berubicin, a novel anthracycline for the treatment of Glioblastoma Multiforme (“GBM”) The approval is the first from a European Ethics Committee The company, which dosed the first patients in its Berubicin program in September, has selected multiple clinical sites across the U.S., Spain, France, Italy, and Switzerland CNS recently closed an $11.5 million private placement It intends to use the net proceeds to fund its clinical trials and preclinical programs, other R&D programs, and for general corporate purposes Clinical stage biotechnology company CNS Pharmaceuticals (NASDAQ: CNSP) is celebrating…

ThursdayJan 20, 2022 12:12 pm

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Present at Virtual Investor 2022 Top Picks Conference

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system (“CNS”), today announced that its CEO John Climaco will participate in the Virtual Investor 2022 Top Picks Conference at 11:00 a.m. ET on Wednesday, Jan. 26, 2022. As part of the virtual event, the company will provide a corporate presentation followed by an interactive Q&A session. In addition to the moderated portion, investors and attendees will have the opportunity to submit questions live during the event or in advance of the conference via www.VirtualInvestorCo.com.…

Site Search

Company Search

Tag: CNS Pharmaceuticals Inc. CNSP